Ticker
Unknown company
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NA... On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE… [+5428 chars]
Source ↗Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The re... On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company's stro… [+3746 chars]
Source ↗Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight,... On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended d… [+5142 chars]
Source ↗Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss... Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against N… [+6260 chars]
Source ↗From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure Novo Nordisk A/S (NYSE:NVO)’s decision to rebrand its day-to-day identity as “Novo” and launch a cultural reset is primarily a strategic response to the comp... Novo Nordisk A/S (NYSE:NVO)'s decision to rebrand its day-to-day identity as "Novo" and launch a cultural reset is primarily a strategic response to the company's loss of momentum in the obesity-drug… [+5386 chars]
Source ↗Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP... During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Co… [+4006 chars]
Source ↗Lilly Launches Foundayo in the UK as NICE Review Continues Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment fo... Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company's oral treatment for weight management and type 2 diabetes is… [+4854 chars]
Source ↗Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong? Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and m... Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expec… [+5111 chars]
Source ↗Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop... On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveragin… [+4889 chars]
Source ↗Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it wi... Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant… [+3898 chars]
Source ↗Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK r... On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK regulatory approval, a new Medicare access … [+4238 chars]
Source ↗Eli Lilly’s Weight-Loss Pill Just Got Its First Foothold in Europe Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orf... Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in E… [+4221 chars]
Source ↗Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serve... On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for "agentic … [+4457 chars]
Source ↗Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO... The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court i… [+6998 chars]
Source ↗Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies? For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But... For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conv… [+7312 chars]
Source ↗Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat? The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years com... The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, … [+8465 chars]
Source ↗Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of... Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier,… [+4101 chars]
Source ↗Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more In this weeks edition of InnovationRx, we look at Lillys 2Q earnings, a cannabis-derived drug for PTSD, Apnimeds IPO and more. To get it in your inbox, subscribe here. Eli Lilly CEO David Ricks Get… [+3037 chars]
Source ↗'Godzilla' weight-loss shot that's more powerful than Ozempic set to be offered to some patients ahead of FDA approval: Find out if you're eligible Eli Lilly announced Monday a limited number of patients can apply for early access to the weight-loss shot retatrutide, ahead of FDA approval. Obese patients who struggle to slim down on today's blockbuster weight-loss shots are set to be offered retatrutide, an experimental drug that helped patients lose up to a quarter of their body weigh… [+4176 chars]
Source ↗Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market? Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to... Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund".A copy of the letter is available todownload here. The Fund gained 11.99% during… [+3958 chars]
Source ↗GLP-1 battle heats up again as Novo claws its way back into race with Lilly The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financia… [+5211 chars]
Source ↗Claude AI Disagrees With President Trump on Eli Lilly (LLY) President Donald Trump recently praised Eli Lily at a public event and called it “a great company” and highlighted its planned $3.5 billion investment for a... President Donald Trump recently praised Eli Lily at a public event and called it "a great company" and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. Howe… [+4356 chars]
Source ↗Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increas… Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health disord… [+1862 chars]
Source ↗Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal July 16 () - Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic... July 16 (Reuters) - Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other … [+1964 chars]
Source ↗Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA. Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum grows for using versions of the drugs as mental health treatments. The tra… [+1605 chars]
Source ↗No disclosed trades for $LLY.